Medical/Pharmaceuticals

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to iRegene's NouvNeu001, Making It the World's First iPSC Therapy with Both FTD and RMAT Recognitions

Designation underscores potential of chemically induced, off-the-shelf cell therapy to address high unmet need in Parkinson's disease, following compelling Phase I clinical data CHENGDU, China, Jan. 19, 2026 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company"), a biotechno...

2026-01-19 21:00 3377

Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis

HONG KONG, Jan. 19, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the Center f...

2026-01-19 19:24 4836

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that through its wholly-owne...

2026-01-19 08:02 8236

WuXi AppTec Receives Double "A" Rating from CDP for Climate Change and Water Security Leadership

SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized on the "A List" for leadership in corporate transparency and performance across both Climate Cha...

2026-01-19 08:00 3515

POMDOCTOR LIMITED Drive Internet Hospital Growth Through Strengthened Strategic Partnerships With Pharmaceutical Companies

GUANGZHOU, China, Jan. 16, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases inChina, today announced significant progress in its strategic collaboration with leading domestic pharmaceutical compani...

2026-01-16 22:00 10868

NUH INAUGURATES NEW CENTRE TO ADVANCE PREDICTIVE AND ACCESSIBLE CARE FOR DIGESTIVE HEALTH

The National University Centre for Digestive Health heralds a new era of care through quicker cross-referrals to surgical specialties, strengthened community partnerships and patient-friendly treatment delivery SINGAPORE, Jan. 16, 2026 /PRNewswire/ -- Digestive health is central to overall well-...

2026-01-16 22:00 4458

Henlius Showcases "Globalisation 2.0" Strategy and Mid-to-Long-Term Innovation Blueprint at JPM 2026

SAN FRANCISCO, Jan. 16, 2026 /PRNewswire/ -- The 44th J.P.Morgan Healthcare Conference (JPMHC) was successfully held inSan Francisco, the United States, fromJanuary 12 to 15. As one of the most influential annual events in the global healthcare sector, JPM serves as a key platform for the capital...

2026-01-16 21:00 4662

Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market

Marks a major milestone in Zylox-Tonbridge's long-term commitment to global expansion Builds an integrated global commercialization platform to accelerate Zylox-Tonbridge's adoption of innovative vascular solutions worldwide Delivers Zylox-Tonbridge's manufacturing and operational synergies acro...

2026-01-16 13:00 8324

The AKG and Ca-AKG of Xin Tianhe have passed the US Self-GRAS certification

SHENZHEN, China, Jan. 15, 2026 /PRNewswire/ -- On January 7, 2026, the AKG and Ca-AKG of Xin Tianhe Biotechnology successfully completed the Self-GRAS scientific evaluation in accordance with the US FDA GRAS standards and were approved and became the first domestic fermentation products that obta...

2026-01-16 12:23 3150

Hugel accelerates global value creation with U.S.-led growth strategy

- President and Global CEO Carrie Strom outlines mid-term growth strategy including global vision, U.S. channel strategy, and portfolio expansion - Hugel targets KRW900 billion in total net sales and 30% of sales from U.S. by 2028 SAN FRANCISCO, Jan. 15, 2026 /PRNewswire/ -- Hugel, Inc., a leadin...

2026-01-16 08:00 4008

SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting

HIGHLIGHTS * Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol. Patient population * With the SECuRE trial continuing to recruit, a total of n...

2026-01-15 22:02 4661

Recognition beyond borders: the life-long commitment of "Grandpa Sugar Pill"

BEIJING, Jan. 15, 2026 /PRNewswire/ -- A news report from China.org.cn on Gu Fangzhou, the father of sugar pills — a live oral polio vaccine:   Recognition beyond borders: the life-long commitment of "Grandpa Sugar Pill" Small, sweet, and slightly gritty when dissolved on the...

2026-01-15 22:00 5112

Aphranel Convenes Cadaver Dissection Class in Thailand Successfully

BANGKOK, Jan. 14, 2026 /PRNewswire/ -- The inaugural "Moyom Biotech • Aphranel Global Expert Advisory Panel • Thailand Anatomy Exchange Conference" was successfully convened inThailand. This high-level forum gathered leading experts from multipleAsia-Pacific countries. Through this concentrated ...

2026-01-15 17:51 3367

GCCL and OPIS Announce Strategic Collaboration to Advance Global Clinical Trial Capabilities

YONGIN, South Korea, Jan. 15, 2026 /PRNewswire/ -- GCCL, a leading South Korea -based provider of clinical trial sample analysis, and OPIS, a global full-service contract research organization (CRO), have signed a Memorandum of Understanding (MOU) on the sidelines of the 44th Annual J.P. Morgan He...

2026-01-15 15:31 3083

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

* Total of 945 integrated projects in 2025, including 74 Phase III clinical projects and 25 commercial manufacturing projects * 209 new integrated projects in 2025 set a new record, with approximately 50% originating from U.S. clients * Complex modalities are WuXi Biologics' core growth engi...

2026-01-15 12:00 6223

Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus

- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the virus war."  - Announces "One Drug, Two Tracks" strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the same drug.  - Dr. Davey Smith: "With this multi-v...

2026-01-15 11:34 4399

Yuyu Pharma Establishes UCLA Office to Accelerate U.S. Pet Industry Expansion

SEOUL, South Korea, Jan. 14, 2026 /PRNewswire/ -- Yuyu Bio and Mervyn's Petcare, pet-focused subsidiaries of Yuyu Pharma, have opened a new office on theUCLA campus, strengthening the company's presence in the United States pet and animal health market. The two companies are now based at Magni...

2026-01-14 22:00 4613

Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

HONG KONG, Jan. 13, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemotherapy against a PD-1 inhibitor plus chemotherapy for th...

2026-01-14 11:54 3988

Celltrion presents innovative drug pipeline and U.S. manufacturing and R&D expansion strategy at the 44th Annual J.P. Morgan Healthcare Conference

* Celltrion outlines a blueprint for innovative drug development built on its antibody expertise * The company highlights its business strategy to scale U.S. manufacturing and R&D capabilities, strengthening its global supply chain, production and operations INCHEON, South Korea, Jan. 13, 202...

2026-01-14 09:18 3932

Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS

NANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral sclerosis (ALS). The initial dosing occurred at Second ...

2026-01-13 20:30 2867
12345678 ... 252